Skip to NavigationSkip to content

Pharmafile - Research and Development

Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary endpoint of...
Despite us nearing the end of the year, the news has not been slowing down at all. Headlines across Europe have been dominated by Brexit negotiations...
When Roche announced that its combination treatment of Tecentriq, alongside its own drug Avastin and chemotherapy, successfully extended progression-...
Sage Therapeutics’ stock rocketed after it announced that Phase 2 results for its treatment for major depressive disorder were positive, sending the...

Features

Andrew Lane, Executive Vice President of Established Pharmaceuticals at Abbott, discusses the key steps to be taken when reaching out to the...

Appointments

Exscientia, an Oxford-based drug design firm which has made headlines this year for its collaboration with GlaxoSmithKline to leverage its own...

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches